[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519958":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":51,"collaborators":28,"id":53,"slug":28,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":28,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":28,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":36,"whyStopped":28,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Shandong Cancer Hospital and Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sintilimab Plus Chemotherapy and Radiotherapy","EXPERIMENTAL","Sintilimab Plus mFFN or NALIRIFOX and Radiation",[13],"Drug: Sintilimab Plus mFFN or NALIRIFOX and Radiation",[15],{"type":16,"name":11,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],[19],"Arm",[21],{"name":22,"affiliation":5,"role":23},"Jinbo Yue, dorctor","PRINCIPAL_INVESTIGATOR",[25,30],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","0531-67626442",null,"yuejinbo@hotmail.com",{"name":31,"role":26,"phone":27,"phoneExt":28,"email":32},"Lei Xu, dorctor","Len.Xu@hotmail.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Department of Radiation Oncology, Shandong Cancer Hospital and Institute","RECRUITING","Jinan","Shandong","0531","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.99722,36.66833,{"lat":46,"lon":45},[49],{"name":50,"role":26,"phone":27,"phoneExt":28,"email":29},"Jinbo Yue, doctor",{"type":23,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Jinbo Yue","100519958",false,"NCT06050317","Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial","Inclusion Criteria:\n\n* ECOG PS 0-1\n* Pathological tissue-confirmed unresectable locally advanced pancreatic cancer\n* Pancreatic cancer patients who have not received systemic anti-tumor therapy\n* Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards\n* A life expectancy of \\> 3 months\n* Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells\u002FL, platelets ≥ 75×109 cells\u002FL, hemoglobin ≥ 9.0 g\u002Fdl\n* AST\\\u003C2.5 × ULN(Upper Limit of Normal), ALT\\\u003C2.5 × ULN,creatinine ≤1.5xULN, total bilirubin \\\u003C ≤1.5 X ULN.\n\nExclusion Criteria:\n\n* Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment\n* Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment\n* Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors\n* Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment\n* Abnormal results of blood routine examinations and liver and kidney and coagulation tests\n* Abnormal function of major organs (14 days before enrollment)\n* Women who are pregnant\n* Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.","ALL","18 Years","75 Years",{"count":63,"type":64},25,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.",[70],"Pancreas Cancer",[72,73,74,75],"Immunothrapy","Chemotherapy","Radiothrapy","Pancreatic cancer","2026-04-27",{"date":78,"type":79},"2026-05-01","ACTUAL",{"date":81,"type":79},"2023-08-18",{"date":83,"type":64},"2026-08-18",{"name":5,"class":6},1]